EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors

Manon Vounckx, Jens Tijtgat, Latoya Stevens, Iris Dirven, Bart Ilsen, Frederik Vandenbroucke, Steven Raeymaeckers, Karolien Vekens, Ramses Forsyth, Xenia Geeraerts, Ivan Van Riet, Julia Katharina Schwarze und 5 weitere

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03751-0 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Manon Vounckx und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Laboratory for Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Bruss…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Radiosurgery, Dendritic Cells, Ipilimumab. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Radiotherapy (RT) synergizes with immune checkpoint blockade (ICB). CD1c(BDCA-1) + /CD141(BDCA-3) + myeloid dendritic cells (myDC) in the tumor microenvironment are indispensable at initiating effector T-cell responses and response to ICB.

Methods

In this phase II clinical trial, anti-PD-1 ICB pretreated oligometastatic patients (tumor agnostic) underwent a leukapheresis followed by isolation of CD1c(BDCA-1) + /CD141(BDCA-3) + myDC. Following hypofractionated stereotactic body RT (3 × 8 Gy), patients were randomized (3:1). Respectively, in arm A (immediate treatment), intratumoral (IT) ipilimumab (10 mg) and avelumab (40 mg) combined with intravenous (IV) pembrolizumab (200 mg) were administered followed by IT injection of myDC; subsequently, IV pembrolizumab and IT ipilimumab/avelumab were continued (q3W). In arm B (contemporary control arm), patients received IV pembrolizumab, with possibility to cross-over at progression. Primary endpoint was 1-year progression-free survival rate (PFS). Secondary endpoints were safety, feasibility, objective response rate, PFS, and overall survival (OS).

Results

Thirteen patients (10 in arm A, eight non-small cell lung cancer, and five melanoma) were enrolled. Two patients crossed over. One-year PFS rate was 10% in arm A and 0% in arm B. Two patients in arm A obtained a partial response, and one patient obtained a stable disease as best response. In arm B, one patient obtained a SD. Median PFS and OS were 21.8 weeks (arm A) versus 24.9 (arm B), and 62.7 versus 57.9 weeks, respectively. An iatrogenic pneumothorax was the only grade 3 treatment-related adverse event.

Conclusion

SBRT and pembrolizumab with or without IT avelumab/ipilimumab and IT myDC in oligometastatic patients are safe and feasible with a clinically meaningful tumor response rate. However, the study failed to reach its primary endpoint. Trial registration number : Clinicaltrials.gov: NCT04571632 (09 AUG 2020). EUDRACT: 2019-003668-32. Date of registration : 17 DEC 2019, amendment 1: 6 MAR 2021, amendment 2: 4 FEB 2022.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedRadiosurgeryDendritic CellsIpilimumabHumansFemaleMaleAgedMiddle AgedAdultAntineoplastic Combined Chemotherapy ProtocolsNeoplasmsThrombomodulinAged, 80 and overCombined Modality TherapyMyeloid CellsGlycoproteinsAntigens, CD1

Stichwörter der Autor:innen

Intratumoral immunotherapyMelanomaMyeloid dendritic cell therapyNon-small lung cell carcinomaStereotactic body radiation therapy

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabavelumabIpilimumabCD1C protein, humanThrombomodulinGlycoproteinsAntigens, CD1

Autor:innen und Institutionen

  • Department of Medical Oncology, Laboratory for Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium. Manon.voun…
  • Department of Medical Oncology, Laboratory for Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.
  • Department of Radiology, Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.
  • Department of Pathology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.
  • Department of Hematology, Stem Cell Laboratory, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.
  • Department of Radiotherapy, Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.

Zitieren

APA

Vounckx, M., Tijtgat, J., Stevens, L., Dirven, I., Ilsen, B., Vandenbroucke, F., Raeymaeckers, S., Vekens, K., Forsyth, R., Geeraerts, X., Van Riet, I., Schwarze, J. K., Tuyaerts, S., Decoster, L., De Ridder, M., Dufait, I., & Neyns, B. (2024). A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03751-0

Vancouver

Vounckx M, Tijtgat J, Stevens L, Dirven I, Ilsen B, Vandenbroucke F, et al. A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03751-0

BibTeX
@article{Vounckx2024,
  author = {Vounckx, Manon and Tijtgat, Jens and Stevens, Latoya and Dirven, Iris and Ilsen, Bart and Vandenbroucke, Frederik and Raeymaeckers, Steven and Vekens, Karolien and Forsyth, Ramses and Geeraerts, Xenia and Van Riet, Ivan and Schwarze, Julia Katharina and Tuyaerts, Sandra and Decoster, Lore and De Ridder, Mark and Dufait, Ines and Neyns, Bart},
  title = {A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03751-0}
}
Kostenlos starten →